Boehringer Ingelheim Patent-Cliff Exposure & CMS Drug Spending Portfolio

Boehringer Ingelheim (Ridgefield, CT): 41 reconciled FDA prescription therapies (83.8% 2025 to 2030 cliff risk), $21.55B 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterRidgefield, CT
Reconciled FDA Portfolio Therapies41
2025 to 2030 Patent-Cliff Revenue Exposure83.8%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$21.55B
2024 Medicare Part D Spend$18.14B
2024 Medicaid Spend$3.40B
California HCAI SB 17 Filings10 WAC filings (max 19.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.